Drugs / PD-1 mAb
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03732547 | Oct 2018 → Oct 2021 | hepatocellular carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-1 mAb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03732547 ↗ |
| Action | Inhibit | “PD-1 blockade” NCT03732547 ↗ |
| Modality | Monoclonal antibody | “Programmed cell death-1 monoclonal antibody” NCT03732547 ↗ |
| Route | Intravenous | “Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.” NCT03732547 ↗ |